Solution
Issue
Issue
Cell manufacturing for
regenerative medicine
In regenerative medicine, cells are cultured and multiplied, and then administered to patients in the desired condition and amount. In other words, cells are the raw material and also contain cells in the final product, and cells are manufactured at each phase of regenerative medicine research and development, clinical trials, and commercial production.
However, at present, the cost of cell production is high, and the price at which cells are provided to patients also remains high, so regenerative medicine has not yet become widespread. Although many promising regenerative medicine seeds have been developed, only a limited number have been put to practical use.
Necessity of specialized personnel
Cells are living organisms and vary from donor to donor. For this reason, at cell manufacturing sites, work in a sterile environment and judgment by specialized personnel are essential for cell culture management and monitoring.
Because it is an analogue process, it is difficult to develop equipment or automate it, which leads to high manufacturing costs.
Therefore, we believe that in order to popularize regenerative medicine, it is necessary to have a method that enables anyone to easily and efficiently produce high-quality cell products and that allows for seamless transitions between the research and development, clinical trial, and commercial production phases.
Solution
Solution
Achieving efficiency in cell manufacturing
for regenerative medicine
Quantitative information on cells and culture conditions are collected on the cloud
Value
– Quantify cell proliferation and changes during culture
– Eliminate the need to enter the culture room (CPC) for confirmation
– Share data in real time with your team
Automated Cell Image Analysis
Strength of our Device:
Lens-less Imaging Technology
Strength of our Device:
Extensive Lineup
Subscription model